Unique ID issued by UMIN | UMIN000000899 |
---|---|
Receipt number | R000001081 |
Scientific Title | Improvement effects of pioglitazone on endothelial function after sirolimus-eluting stent (Cypher stent) implantation: a randomized, open rabelled, prospective study. |
Date of disclosure of the study information | 2007/11/19 |
Last modified on | 2011/03/10 16:46:53 |
Improvement effects of pioglitazone on endothelial function after sirolimus-eluting stent (Cypher stent) implantation: a randomized, open rabelled, prospective study.
Improvement effects of pioglitazone on endothelial function after Cypher stent implantation: a randomized study.
Improvement effects of pioglitazone on endothelial function after sirolimus-eluting stent (Cypher stent) implantation: a randomized, open rabelled, prospective study.
Improvement effects of pioglitazone on endothelial function after Cypher stent implantation: a randomized study.
Japan |
coronary artery disease
Cardiology |
Others
NO
To evaluate the efficacy of Pioglitazone for endothelial function after sirolimus-eluting stent (Cypher stent) implantation for non-diabetic patient with coronary artery disease.
Efficacy
Coronary endothelial function with acetylcholine by quantitative coronary angiography.
Plasma glucose, HbA1C, total cholesterol, triglyceride, LDL, HDL, MDA-LDL, HMW-adiponectin and hs-CRP.
Major adverse cardiovascular event and harmful effect of pioglitazone.
Plasma GOT, GPT, T-BIL, ALP, LDH, CPK and BNP
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Intervention group: Start to take pioglitazone 15mg per day after percutaneous coronary angioplasty and increase a dose to 30mg per day at 14days after angioplasty. And continue in 9 months.
Control group: Take no pioglitazone in 9 months after percutaneous coronary angioplasty.
20 | years-old | <= |
85 | years-old | > |
Male and Female
Patient who don't have type 2 diabetes mellitus with undergoing percutaneous coronary angioplasty.
Acute myocardial infarction, heart failure, severe hepatic or renal dysfunction, already to take pioglitazone, pregnancy and in-stent restenotic lesion.
50
1st name | |
Middle name | |
Last name | Issei Komuro |
Chiba University Graduate School of Medicine
Division of cardiovascular science and medicine
1-8-1 Inohana, Chu-o ku, Chiba city, Chiba, JAPAN
043-222-7171
1st name | |
Middle name | |
Last name | Hideki Kitahara |
Chiba University Graduate School of Medicine
Division of cardiovascular science and medicine
043-222-7171
Chiba University Graduate School of Medicine
none
Self funding
NO
2007 | Year | 11 | Month | 19 | Day |
Unpublished
Completed
2007 | Year | 04 | Month | 01 | Day |
2007 | Year | 04 | Month | 01 | Day |
2010 | Year | 04 | Month | 01 | Day |
2007 | Year | 11 | Month | 19 | Day |
2011 | Year | 03 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001081
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |